Acceleron Pharma Inc
NASDAQ:XLRN 3:59:54 PM EDT
| Market Cap (Intraday) | 9.73B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $144.18 |
| 50-Day MA | $128.09 |
| 200-Day MA | $127.51 |
Acceleron Pharma Inc Stock, NASDAQ:XLRN
128 Sidney Street, Cambridge, Massachusetts 02139
United States of America
Phone: +1.617.649.9200
Number of Employees: 312
Description
Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.